Tacrolimus Market Size, Share, Demand Trends and Forecast 2034
Tacrolimus Market Growth, Size, Trends Analysis - By Product Type, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jun-2025 | Report ID: PHAR2511 | Pages: 1 - 210 | Formats*: |
| Category : Pharmaceutical | |||
Tacrolimus Market Introduction and Overview
According to SPER Market Research, the Global Tacrolimus Market is estimated to reach USD 12.35 billion by 2034 with a CAGR of 5.86%.
The report includes an in-depth analysis of the Global Tacrolimus Market, including market size and trends, product mix, Applications, and supplier analysis. The market for tacrolimus was estimated to be worth USD 6.99 billion in 2024 and is expected to expand at a 5.86% annual pace between 2025 and 2034. The increasing frequency of autoimmune illnesses and the growing number of organ transplant procedures are the main causes of this rise. The growth in organ transplants is linked to rising end-stage organ failures, greater awareness of organ donation, and advancements in medical technology. Conditions like chronic kidney disease and heart failure, influenced by aging populations and lifestyle diseases, have raised the demand for transplants.
By Product Insights
The global tacrolimus market is divided into three categories: tablets and capsules, injections, and others. In 2024, the tablets and capsules category dominated the market. This is because tablets and capsules are more convenient and easier for patients to take, resulting in higher drug adherence, which is critical for immunosuppressive therapy.
By Application Insights
Based on application, the market is divided into three segments: dermatitis, immunosuppression, and others. The immunosuppression segment dominated the market in 2024 and is expected to maintain its dominance during the forecast period. Immunosuppressive medications are critical for preventing organ rejection in transplant recipients. The increasing frequency of organ transplant surgeries will fuel demand for this drug during the forecast period.
By End-User Insights
There are several end-user segments within the worldwide tacrolimus market, including hospitals and clinics. In 2024, the hospital segment held the biggest market share and dominated the market. Hospitals with specialised transplant centres frequently see an increase in the number of transplant procedures performed, which in turn leads to a larger need for tacrolimus. Additionally, government programs that facilitate organ transplantation and offer funding for immunosuppressive drugs can increase hospital demand.
Regional Insights
North America led the tacrolimus market in 2024 and is expected to see significant growth. The region has a strong healthcare system with specialized centers and hospitals for organ transplants and related treatments. This advanced infrastructure is likely to support market growth in the future. Additionally, many patients in North America have health insurance, which helps them afford medications like tacrolimus, further increasing demand for the drug.
Market Competitive Landscape
Large multinational organisations and small and medium-sized enterprises compete fiercely in the tacrolimus industry. One important market strategy is the creation and introduction of new, cutting-edge products based on different formulas. Among the major players in the market are Abbott Laboratories, Astellas Pharma Inc., and Glenmark Pharmaceuticals Ltd.
Recent Developments:
- The U.S. FDA approved Nexus Pharmaceuticals' 5 mg/mL Tacrolimus Injection in February 2025. With this approval, Tacrolimus Injection's first and only single-dose vial is now available. For patients in need of immunosuppressive treatment, like those receiving organ transplants, it will provide new hope.
- The National Medical Products Administration (NMPA) of China authorised Biocon Pharma Limited's Tacrolimus capsules in strengths of 0.5 mg, 5 mg, and 1 mg for organ transplant recipients in January 2025.
- In August 2023, Glenmark Pharmaceuticals received FDA approval for their generic version of Leo Pharma's Protopic Ointment (0.03%), Tacrolimus ointment (0.03%). The goal of this approval is to increase the company's revenue generation, brand awareness, and reputation.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product Type, By Application, By End-User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Abbott Laboratories, Astellas Pharma Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, GSK plc, Lupin Pharmaceuticals Ltd, Novartis, Pfizer Inc, Takeda Pharmaceutical Company Limited. |
Key Topics Covered in the Report
- Global Tacrolimus Market Size (FY’2021-FY’2034)
- Overview of Global Tacrolimus Market
- Segmentation of Global Tacrolimus Market By Product Type (Tablets & Capsules, Injections, Others)
- Segmentation of Global Tacrolimus Market By Application (Immunosuppression, Dermatitis, Others)
- Segmentation of Global Tacrolimus Market By End-User (Hospitals, Clinics, Others)
- Statistical Snap of Global Tacrolimus Market
- Expansion Analysis of Global Tacrolimus Market
- Problems and Obstacles in Global Tacrolimus Market
- Competitive Landscape in the Global Tacrolimus Market
- Details on Current Investment in Global Tacrolimus Market
- Competitive Analysis of Global Tacrolimus Market
- Prominent Players in the Global Tacrolimus Market
- SWOT Analysis of Global Tacrolimus Market
- Global Tacrolimus Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Tacrolimus Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tacrolimus Market
7. Global Tacrolimus Market, By Product Type (USD Million) 2021-2034
- 7.1. Tablets & Capsules
- 7.2. Injections
- 7.3. Others
8. Global Tacrolimus Market, By Application (USD Million) 2021-2034
- 8.1. Immunosuppression
- 8.2. Dermatitis
- 8.3. Others
9. Global Tacrolimus Market, By End-User (USD Million) 2021-2034
- 9.1. Hospitals
- 9.2. Clinics
- 9.3. Others
10. Global Tacrolimus Market, (USD Million) 2021-2034
- 10.1. Global Tacrolimus Market Size and Market Share
11. Global Tacrolimus Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Abbott Laboratories
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Astellas Pharma Inc
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Biocon Ltd
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. F. Hoffmann-La Roche Ltd
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Glenmark Pharmaceuticals Ltd
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. GSK plc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Lupin Pharmaceuticals Ltd
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Novartis
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4 .Recent developments
- 12.9. Pfizer Inc
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Takeda Pharmaceutical Company Limited
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Tacrolimus Market is projected to reach USD 12.35 billion by 2034, growing at a CAGR of 5.86% during the forecast period.
Tacrolimus Market grew in Market size from 2025. The Market is expected to reach USD 12.35 billion by 2034, at a CAGR of 5.86% during the forecast period.
Tacrolimus Market CAGR of 5.86% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Tacrolimus Market size is USD 12.35 billion from 2025 to 2034.
Tacrolimus Market is covered By Product Type, By Application, By End-User
The North America is anticipated to have the highest Market share in the Tacrolimus Market.
Abbott Laboratories, Astellas Pharma Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, GSK plc, Lupin Pharmaceuticals Ltd, Novartis, Pfizer Inc, Takeda Pharmaceutical Company Limited.
The report includes an in-depth analysis of the Global Tacrolimus Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
